CHMP recommends midostaurin for FLT3+ AML, SM

Midostaurin (Rydapt)
Photo courtesy of Novartis
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending approval for midostaurin (Rydapt®) as a treatment for acute myeloid leukemia (AML) and systemic mastocytosis (SM). If approved by the European Commission, midostaurin would be used in combination with standard daunorubicin and cytarabine... [Read Article]

Combo may be option for elderly patients with untreated AML

Andrew Wei, MBBS, PhD
The combination of venetoclax and low-dose cytarabine (VEN+LDAC) appears to be a feasible treatment option for elderly patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. In a phase 1/2 study of such patients, VEN+LDAC was considered well-tolerated, conferring moderate myelosuppression and largely low-grade non-hematologic... [Read Article]

Company discontinues phase 3 trial of vadastuximab talirine in AML

AML cells
On the advice of the Independent Data Monitoring Committee, Seattle Genetics is discontinuing the phase 3 CASCADE clinical trial of vadastuximab talirine as frontline treatment in older patients with acute myeloid leukemia (AML). The company is also suspending patient enrollment and treatment in all its vadastuximab trials, including the ongoing phase 1/2 trial... [Read Article]

‘Admirable’ overall survival attainable in AML with enasidenib

McCormick Place during
ASCO 2017 Annual Meeting
Photo © ASCO/Danny Morton 2017
The experimental mutant IDH2 (mIDH2) inhibitor enasidenib has produced “admirable” overall survival in patients with mIDH2 relapsed or refractory acute myeloid leukemia (AML), according to Eytan M. Stein, MD, an investigator on the phase 1 dose escalation and expansion study. Patients who achieved... [Read Article]

Deep molecular responses achievable in AML pts treated with gilteritinib

Lobby of McCormick Place during ASCO 2017
Photo © ASCO/Danny Morton 2017
Next generation sequencing (NGS) has shown that the FLT3 inhibitor gilteritinib can produce deep molecular responses in a subset of patients with acute myeloid leukemia (AML), according to new research. Gilteritinib is a highly selective FLT3/AXL inhibitor that is active against FLT3-ITD and... [Read Article]

Majority of AML patients do not receive recommended molecular genetic testing

DNA helices
Image courtesy of the
National Institute of
General Medical Sciences
While 67% of newly diagnosed patients with acute myeloid leukemia (AML) receive some genetic testing, only 9% receive all 7 of the genetic tests recommended by the National Comprehensive Cancer Network (NCCN), according to new research. The data comes from the CONNECT MDS/AML... [Read Article]

Differences emerge in new guidelines for managing FN in kids

Doctor evaluating patient
Photo courtesy of the CDC
A multidisciplinary, international panel of experts has updated earlier clinical practice guidelines on managing fever and neutropenia (FN) in children with cancer and in those undergoing hematopoietic stem cell transplantation (HSCT). And while most of the recommendations remained unchanged from the 2012 guidelines, a few key... [Read Article]